A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease
about
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V)Diagnosis and therapy of non-variceal upper gastrointestinal bleedingElective Urological Surgery Following Coronary Stent Implantation: To Whom, How To Do It?Clinical review: Traumatic brain injury in patients receiving antiplatelet medicationCoronary stent management in elective genitourinary surgeryEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsAdherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksProthrombotic and hemorrhagic effects of aspirin.Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgeryThrombotic events associated to aspirin therapy.Perioperative cardiovascular complications versus perioperative bleeding in consecutive patients with known cardiac disease undergoing non-cardiac surgery. Focus on antithrombotic medication. The PRAGUE-14 registryClinical importance of aspirin and clopidogrel resistanceRenal biopsy practice: What is the gold standard?Medication adherence: WHO cares?Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines.Risk factors for early and delayed post-operative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agentsPrevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients.Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary careRisk is not our business: safety of thoracic surgery in patients using antiplatelet therapy.[Current Practice in the Transurethral Treatment of Benign Prostatic Obstruction under Oral Anticoagulants : A Nation-wide Survey].Depression and coronary heart diseaseManagement by the intensivist of gastrointestinal bleeding in adults and children.Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelinesPercutaneous coronary intervention in nonagenarians: pros and cons.Aspirin insensitive thrombophilia: transcript profiling of blood identifies platelet abnormalities and HLA restrictionTo stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us?Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease.Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.Appropriate secondary prevention of acute atherothrombotic events and strategies to improve guideline adherence.The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label studyLong-term effect of chronic oral anticoagulation: focus on coronary artery disease.Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.Aspirin allergy desensitization in cerebrovascular disease. A report of two cases, literature review and management guide for the neurointerventionalist.Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction.
P2860
Q24642679-2A90353D-4EF3-48BE-BA52-CC7E1D7A749AQ26777626-1DB4E5E0-71ED-4A7A-AFAA-4F62B0B6F572Q26801463-334686AF-FC9A-4237-A765-93A0756B3347Q26830409-79272814-6C0C-40E1-AC18-72F4A7BB3834Q26860920-7715545E-B1CE-4D62-8EBA-1D1E86CF93F1Q26995752-E51B3AAE-94D1-4EE0-BC1C-0FA38ED8BA58Q30248710-74CCFB42-9EA3-4518-93F6-226AFA856149Q30629677-370AE63F-AAD2-4058-B41D-AE2BF6987E90Q33349385-C6400D6D-5A15-4FDA-A144-C3D088A7EDC0Q33401497-397B1B12-0B74-450E-A166-4A2E412ADC9CQ33755419-ECB96BB1-1807-4C41-80BD-2CA2575F4E2BQ34111104-55C6E906-8E0D-483E-96B2-2C0F7404F761Q34161205-729A7273-08C6-44BF-B045-60AFF4E0E90BQ34390050-54071D33-8608-40FA-87AF-8F96A3998F2AQ34453300-7CE2E25C-3F30-4A9C-808C-67725C2FC49DQ34627451-4C4EB332-D016-4530-968F-1B4035BE77A3Q34667405-EF72DCB5-37D6-42A7-BD6B-A9ADB3CC7C4BQ34873381-7E5D0E94-4454-45FE-9CDB-F4E923CF6E73Q34935769-0D5959E2-3A52-407D-918B-2B76826F0F2BQ35112520-2C7731BD-E2DE-40AD-A2F2-DBA76ADEE5AEQ35116433-3C67C56F-1A01-41C3-8DFF-5C855FA4ACDDQ35758378-4C8ED645-A3F9-44BD-AAA6-8490495F6F19Q35907115-1D253086-DECD-4F68-B868-DD4B0B63CC3CQ36446704-7ECEA5DE-1E32-4ABF-8E1C-8439BECD379DQ36478606-5C376D74-3B65-47E4-B1AD-A73713BBF808Q36682317-92374616-68CD-43B5-969C-4396FDA5924DQ36769847-AE22A255-1D79-4260-BBBC-2872A700CA77Q37018788-7FBB4837-7F47-4128-9BBC-2B485A2B933DQ37121465-C6B0CBA2-633E-4DC8-914C-89B599765543Q37148386-260B4DFA-5367-4810-8BAE-A70FBA01E6EBQ37240704-13E7D1AA-F39E-43F5-975D-63CF72D451D7Q37300872-095A16DE-B7AA-41C7-9DD1-A66231331F7BQ37348911-D380A381-CFA2-46AD-9E74-FF62EB183DE0Q37380499-5F99F1EE-5DA0-4A84-88FA-DFA8996C1839Q37380507-2C02433A-A236-45F8-AEB9-2C46CAC6A73BQ37396871-B81EC4DC-8DF8-4459-B46C-1711296D8AC4Q37486610-7DAEB140-22A2-4FAC-A7B4-F31B24F38EBBQ37532491-D2F98D63-EB00-4847-BCDF-F37BC2DFD377Q37676410-2059C339-CCC4-44AF-98A1-2CB1730C324FQ37702654-8D6DDBB4-5EB6-4664-8ACF-36DF06417EC1
P2860
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease
description
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im November 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: November 2006)
@en
vedecký článok (publikovaný 2006-11)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd in 2006-11)
@nl
наукова стаття, опублікована в листопаді 2006
@uk
مقالة علمية (نشرت في نوفمبر 2006)
@ar
name
A systematic review and meta-a ...... sk for coronary artery disease
@ast
A systematic review and meta-a ...... sk for coronary artery disease
@en
A systematic review and meta-a ...... sk for coronary artery disease
@nl
type
label
A systematic review and meta-a ...... sk for coronary artery disease
@ast
A systematic review and meta-a ...... sk for coronary artery disease
@en
A systematic review and meta-a ...... sk for coronary artery disease
@nl
prefLabel
A systematic review and meta-a ...... sk for coronary artery disease
@ast
A systematic review and meta-a ...... sk for coronary artery disease
@en
A systematic review and meta-a ...... sk for coronary artery disease
@nl
P2093
P31
P921
P3181
P356
P1476
A systematic review and meta-a ...... sk for coronary artery disease
@en
P2093
Antonio Abbate
Francesco Burzotta
Giuseppe G L Biondi-Zoccai
Imad Sheiban
Luca Testa
Marzia Lotrionte
Massimiliano Fusaro
Pierfrancesco Agostoni
P304
P3181
P356
10.1093/EURHEARTJ/EHL334
P407
P577
2006-11-01T00:00:00Z